TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Na
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

DBV Technologies announced positive topline results from its Phase 3 VITESSE trial evaluating VIASKIN® Peanut Patch for treating peanut allergies in children aged 4-7 years. The trial met its primary endpoints, representing a significant milestone for the company's immunotherapy treatment program.

Insights
DBVT   positive

The company announced positive topline results from a Phase 3 clinical trial, which is a significant regulatory and clinical achievement. Meeting primary endpoints in a late-stage trial typically supports potential regulatory approval and commercialization prospects for the therapeutic candidate.